IBRX - IBRX FINAL DEADLINE ALERT: Hagens Berman National Trial Attorneys Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm's Attorneys Before Aug. 29th Deadline in Securities Fraud Class Action | Benzinga

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ:IBRX) investors who suffered substantial losses to submit your losses now.

Class Period: May 23, 2022 – May 10, 2023
Lead Plaintiff Deadline: Aug. 29, 2023
Visit: www.hbsslaw.com/investor-fraud/ibrx
Contact An Attorney Now: IBRX@hbsslaw.com
                                          844-916-0895

ImmunityBio, Inc. (IBRX) Securities Fraud Class Action:

The litigation focuses on ImmunityBio's statements about the manufacturing and commercial prospects for its lead product candidate (Anktiva) for the treatment of patients with certain non-muscle invasive bladder cancer.

The complaint alleges that Defendants made false and misleading statements and failed to disclose that: (1) ImmunityBio conducted insufficient due diligence to ...

IBRX) Investors with Substantial Losses to Contact Firm's Attorneys Before Aug. 29th Deadline in Securities Fraud Class Action>Full story available on Benzinga.com